Literature DB >> 24479862

Neonatal invasive fungal infection in England 2004-2010.

C Oeser1, S Vergnano, R Naidoo, M Anthony, J Chang, P Chow, P Clarke, N Embleton, N Kennea, S Pattnayak, B Reichert, T Scorrer, I Tiron, T Watts, M Sharland, P T Heath.   

Abstract

Rates of invasive fungal infection are highest among neonates, especially those of low birthweight. This study aimed to describe the current epidemiology of invasive neonatal fungal infections in a UK neonatal infection surveillance network. From 2004 to 2010 prospective multicentre surveillance was conducted by 14 neonatal units using a web-based database. Clinicians then completed a standardized pro forma for each positive fungal blood and/or cerebrospinal fluid culture. The overall incidence was 2.4/1000 neonatal unit admissions and was highest among babies <1000 g (extreme low birthweight, 18.8/1000). Only five infants (6%) were >1500 g. The majority of infections were caused by Candida albicans (59; 69%) and Candida parapsilosis (17; 20%); 33% of infants had received antifungal prophylaxis. Known risk factors (use of central venous catheter, parenteral nutrition, previous antibiotic use) were common among cases. The attributable case fatality rate was 21% (18/84). Extreme low birthweight infants remain at highest risk of invasive fungal infection and prophylaxis should be particularly considered for this group. The number needing to receive prophylaxis to prevent one case varies significantly among units, hence unit-specific decisions are required. Further research is still needed into the optimal empiric and therapeutic strategies.
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Candidaemia; epidemiology; fungal; neonatal; prophylaxis

Mesh:

Year:  2014        PMID: 24479862     DOI: 10.1111/1469-0691.12578

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  18 in total

Review 1.  Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants.

Authors:  Jemma Cleminson; Nicola Austin; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2015-10-24

Review 2.  Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.

Authors:  Nicola Austin; Jemma Cleminson; Brian A Darlow; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2015-10-24

Review 3.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

Review 4.  Challenges in developing a consensus definition of neonatal sepsis.

Authors:  Matthew McGovern; Eric Giannoni; Helmut Kuester; Mark A Turner; Agnes van den Hoogen; Joseph M Bliss; Joyce M Koenig; Fleur M Keij; Jan Mazela; Rebecca Finnegan; Marina Degtyareva; Sinno H P Simons; Willem P de Boode; Tobias Strunk; Irwin K M Reiss; James L Wynn; Eleanor J Molloy
Journal:  Pediatr Res       Date:  2020-03-03       Impact factor: 3.756

5.  Contemporary Trends in Global Mortality of Sepsis Among Young Infants Less Than 90 Days: A Systematic Review and Meta-Analysis.

Authors:  Ming Ying Gan; Wen Li Lee; Bei Jun Yap; Shu Ting Tammie Seethor; Rachel G Greenberg; Jen Heng Pek; Bobby Tan; Christoph Paul Vincent Hornik; Jan Hau Lee; Shu-Ling Chong
Journal:  Front Pediatr       Date:  2022-06-03       Impact factor: 3.569

6.  Isolation and drug susceptibility of Candida parapsilosis sensu lato and other species of C. parapsilosis complex from patients with blood stream infections and proposal of a novel LAMP identification method for the species.

Authors:  Plinio Trabasso; Tetsuhiro Matsuzawa; Renata Fagnani; Yasunori Muraosa; Kenichiro Tominaga; Mariangela Ribeiro Resende; Katsuhiko Kamei; Yuzuru Mikami; Angelica Zaninelli Schreiber; Maria Luiza Moretti
Journal:  Mycopathologia       Date:  2014-12-07       Impact factor: 2.574

7.  Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.

Authors:  S Leroux; E Jacqz-Aigrain; V Elie; F Legrand; C Barin-Le Guellec; B Aurich; V Biran; B Dusang; S Goudjil; S Coopman; R Garcia Sanchez; W Zhao; P Manzoni
Journal:  Br J Clin Pharmacol       Date:  2018-06-21       Impact factor: 4.335

8.  Management of Invasive Fungal Disease in Neonates and Children.

Authors:  Laura Ferreras-Antolín; Mike Sharland; Adilia Warris
Journal:  Pediatr Infect Dis J       Date:  2019-06       Impact factor: 2.129

9.  C-reactive protein for diagnosing late-onset infection in newborn infants.

Authors:  Jennifer Valeska Elli Brown; Nicholas Meader; Jemma Cleminson; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2019-01-14

Review 10.  Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.

Authors:  Paolo Manzoni; Chunzhang Wu; Lorraine Tweddle; Emmanuel Roilides
Journal:  Pediatr Infect Dis J       Date:  2014-11       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.